Latest Biotech News

Mirum Pharmaceuticals’ Atebrioz won FDA approval for fibrodysplasia ossificans progressiva (FOP), adding a third approved option for the ultra-rare condition characterized by progressive bone...

A new AI approach is designed to flag when it is uncertain about whether metastatic non-small cell lung cancer patients will respond to first-line chemoimmunotherapy. By incorporating confidence...

A BLA filing for ifinatamab deruxtecan was voluntarily withdrawn in previously treated extensive-stage small cell lung cancer. The decision reshapes the near-term regulatory path for the ADC in a...

A jury found that Eli Lilly breached an implied covenant of good faith and fair dealing in a collaboration covering Nektar Therapeutics’ lead immuno-oncology candidate rezpegaldesleukin. Nektar...

Medable said an independent analysis with Tufts Center for the Study of Drug Development (CSDD) found its Clinical Monitoring Agent can improve the efficiency of clinical research monitoring and...

Researchers reported a 60-fold boost in the performance of a compact CRISPR nuclease after engineering changes to the enzyme and guide RNA design. The work, published in Molecular Systems Biology,...

The LAVA-CRLM randomized trial reported a head-to-head comparison of radiation and heat-based ablation for colorectal liver metastases. The study addresses a longstanding evidence gap by directly...

A large investigation reported that more than half of patients receiving cellular therapies develop orthostatic hypotension, a dangerous blood pressure drop on standing, within the first month...

A review highlighted how metabolism-focused re-engineering could address CAR-T’s performance limitations in solid tumors, where nutrient and microenvironment constraints can blunt T-cell function....

New work proposes a modeling approach that uses AI combined with a clinical signal framework to predict colorectal cancer risk, aiming to standardize how risk is stratified earlier in the disease...

Mirum Pharmaceuticals’ Atebrioz (atebrioz) has won FDA approval for fibrodysplasia ossificans progressiva (FOP), adding a third approved therapy for the ultra-rare condition. Mirum acquired...

Nektar Therapeutics’ legal dispute with Eli Lilly took another turn as investors digested a $90 million jury award in Nektar’s favor over Lilly’s termination of a co-development collaboration. The...

The LAVA-CRLM trial has delivered a first direct comparison of two curative-intent options for colorectal liver metastases, with radiation matching heat-based ablation. In the randomized study...

A dose-expansion phase study in advanced endometrial cancer reported durable tumor shrinkage when an oral Wnt-blocking agent was combined with lenvatinib after prior immunotherapy failure. The...

Boehringer Ingelheim’s ifinatamab deruxtecan development hit a setback as the company voluntarily withdrew its biologics license application in previously treated extensive-stage small cell lung...

A large investigation has found that most patients receiving lifesaving cellular therapies develop hidden blood pressure drops upon standing within their first month. The study links a majority...

Researchers built a standardized rulebook for a key clinical milestone—time to subsequent therapy (TTST)—aimed at helping oncology trials and clinicians decide when patients should move off a...

A review in the Journal of Translational Medicine argues that metabolism-focused engineering could be a path to make CAR-T cells work better in solid tumors. It outlines how tumor nutrient...

A compact CRISPR nuclease, CgCas12n, has been engineered into a higher-performance genome-editing platform with a reported 60-fold power boost. In a study published in Molecular Systems Biology,...

An AI model is helping identify when clinicians should be cautious about predicting cancer treatment success. For metastatic non-small cell lung cancer treated with first-line chemoimmunotherapy,...